Adherence to adjuvant endocrine therapy in women with breast cancer

Journal of Oncology Pharmacy Practice

Volumn 19, Issue 2, 2013, Pages 105-110

  Danilak, Melanie ^a   Chambers, Carole R ^a  

^a CROSS CANCER INSTITUTE   (Canada)

Author keywords

Adherence; aromatase inhibitors; breast cancer; endocrine therapy; tamoxifen

Indexed keywords

ANASTROZOLE; LETROZOLE; TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; PATIENT COMPLIANCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

ADHERENCE; AROMATASE INHIBITORS; BREAST CANCER; ENDOCRINE THERAPY; TAMOXIFEN;

ADULT; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; FOLLOW-UP STUDIES; HUMANS; MEDICATION ADHERENCE; MIDDLE AGED; RETROSPECTIVE STUDIES; TAMOXIFEN; TIME FACTORS;

EID: 84879289713     PISSN: 10781552     EISSN: 1477092X     Source Type: Journal    
DOI: 10.1177/1078155212455939     Document Type: Article

References (28)

1. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005 ; 353: 487-497
2. Canadian Cancer Society, Toronto: Canadian Cancer Society. http://www.cancer.ca/canada-wide/about%20cancer/cancer%20statistics/ stats%20at%20a%20glance/breast%20cancer.aspx?sc-lang=en (2009, accessed 27 May 2009).
3. Albertabreast.com, Alberta, c2000-09. http://www.albertabreast.com/ northern/ (accessed 20 January 2009).
4. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials. Lancet. 2005 ; 365: 1687-1717
5. Results of the ATAC (Arimidex, Tamoxifen, Alone or in combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet. 2005 ; 365 (9453). 60-62
6. Coombes RC, Kilburn LS, Snowdon CF, et al. Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet. 2007 ; 369 (9561). 559-570
7. Coates AS, Keshaviah A, Thürlimann B, et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol. 2007 ; 25 (5). 486-492
8. Goss PE, Ingle JN, Martino S, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med. 2003 ; 349 (19). 1793-1802
9. Waterhouse DM, Calzone KA, Mele C, et al. Adherence to oral tamoxifen: a comparison of patient self-report, pill counts, and microelectronic monitoring. J Clin Oncol. 1993 ; 11 (6). 1189-1197
10. Murthy V, Bharia G, Sarin R. Tamoxifen non-compliance: does it matter?. Lancet Oncol. 2002 ; 3: 654-654
11. Demissie S, Silliman RA, Lash TL. Adjuvant tamoxifen: predictors of use, side effects, and discontinuation in older women. J Clin Oncol. 2001 ; 19 (2). 322-328
12. Partridge AH, Wang PS, Winer EP, et al. Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol. 2003 ; 21 (4). 602-606
13. Fink AK, Gurwitz J, Rakowski W, et al. Patient beliefs and tamoxifen discontinuance in older women with estrogen receptor-positive breast cancer. J Clin Oncol. 2004 ; 22 (16). 3309-3315
14. Grunfeld EA, Hunter MS, Sikka P, et al. Adherence beliefs among breast cancer patients taking tamoxifen. Patient Educ Couns. 2005 ; 59 (1). 97-102
15. Barron TI, Connolly R, Bennett K, et al. Early discontinuation of tamoxifen: a lesson for oncologists. Cancer. 2007 ; 109 (5). 832-839
16. Lash TL, Fox MP, Westrup JL, et al. Adherence to tamoxifen over the five-year course. Breast Cancer Res Treat. 2006 ; 99: 215-220
17. Kahn KL, Schneider EC, Malin JL, et al. Patient centered experiences in breast cancer: predicting long-term adherence to tamoxifen use. Med Care. 2007 ; 45 (5). 431-439
18. Hadji P, Ziller V, Holzhauer W, et al. Compliance with tamoxifen and anastrozole in the adjuvant treatment of women with breast cancer. Breast Cancer Res Treat. 2007 ; 106 (Suppl 1). S146 - S146
19. Bramwell V, Pritchard K, Dongsheng T, et al. How compliant are patients with oral hormonal therapies? Data from a randomized placebo controlled study of tamoxifen, after adjuvant chemotherapy, in premenopausal women with early breast cancer: NCIC CTG MA.12. Breast Cancer Res Treat. 2007 ; 106 (Suppl 1). S144 - S144
20. Dent SF, Hopkins S, Di Valentin T, et al. Adjuvant aromatase inhibitors in early breast cancer - toxicity and adherence. Important observations in clinical practice. Breast Cancer Res Treat. 2007 ; 106 (Suppl 1). S111 - S111
21. Partridge AH, LaFountain A, Mayer E, et al. Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer. J Clin Oncol. 2008 ; 26 (4). 556-562
22. Owusu C, Buist DSM, Field T, et al. Predictors of tamoxifen discontinuation among older women with estrogen receptor-positive breast cancer. J Clin Oncol. 2008 ; 26: 549-555
23. Guth U, Huang DJ, Schotzau A, et al. Target and reality of adjuvant endocrine therapy in postmenopausal patients with invasive breast cancer. Br J Cancer. 2008 ; 99 (3). 428-433
24. McCowan C, Shearer J, Donnan PT, et al. Cohort study examining tamoxifen adherence and its relationship to mortality in women with breast cancer. Br J Cancer. 2008 ; 99: 1763-1768
25. Alberta Health Services. Outpatient cancer drug benefit program. Alberta, Canada: Alberta Health Services. http://www.albertahealthservices.ca/ps- 1025651-drug-benefit-list.pdf (2012, accessed 1 May 2012).
26. e-CPS. Ottawa, ON: Canadian Pharmacists Association, c2005. https://www-e-therapeutics-ca.login.ezproxy.library.ualberta.ca/cps. showMonograph.action (accessed 1 June 2009; files updated every two weeks).
27. Dobish RB, Tulloch KJ, Chambers CR. Implementation of a telephone callback service for ambulatory oncology patients. J Oncol Pharm Practice. 2003 ; 9: 21-28
28. Partridge AH, Avorn J, Wang PS, et al. Adherence to therapy with oral antineoplastic agents. J Natl Cancer Inst. 2002 ; 94 (9). 652-661